This NDC is on FDA's drug shortage list (posted Jul 18, 2023)
Reported reason: Delay in shipping of the drug
Product Information
VICTOZA 2-PAK 18 MG/3 ML PEN is a brand product labeled by Novo Nordisk, priced at $87.7480 per ML under NDC 00169406012. Its NADAC has been published 661 times since Nov 28, 2013.
FDA first approved this application on Jan 25, 2010. Its Orange Book therapeutic-equivalence code is AP1.
The High Outlier badge above means this manufacturer's average price in the liraglutide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/mL
Manufacturer
Novo NordiskNDC
00169406012
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
LIRAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA022341FDA Approved
1/25/2010
TE Code
AP1
On Market Since
1/25/2010
Pharmacological Classes
Price Statistics
The NADAC for VICTOZA 2-PAK 18 MG/3 ML PEN has been published 661 times since Nov 28, 2013, and over the history we have for it it has risen 65.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $87.7480 per ML |
|---|---|
| All-time high | $119.6468 (Jan 3, 2024) |
| All-time low | $53.0874 (Nov 28, 2013) |
| 52-week high | $87.8946 |
| 52-week low | $87.5306 |
| Median price | $87.7154 |
| Average price | $91.2966 |
| Largest weekly change | -27.0% (Jan 10, 2024) |
| Weeks tracked | 661 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 65% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
liraglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VICTOZA 2-PAK 18 MG/3 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for VICTOZA 2-PAK 18 MG/3 ML PEN, manufactured by Novo Nordisk, is $87.7480 per ML (NDC 00169406012), effective Sep 30, 2026.
How has the price of VICTOZA 2-PAK 18 MG/3 ML PEN changed over time?
Over the history we have for it, the NADAC for VICTOZA 2-PAK 18 MG/3 ML PEN has risen 65.3%. It has been tracked across 661 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VICTOZA 2-PAK 18 MG/3 ML PEN?
Since Nov 28, 2013, the NADAC for VICTOZA 2-PAK 18 MG/3 ML PEN has ranged from a low of $53.0874 (Nov 28, 2013) to a high of $119.6468 (Jan 3, 2024), with a median of $87.7154 per ML.
Are there cheaper alternatives to VICTOZA 2-PAK 18 MG/3 ML PEN?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIRAGLUTIDE 3-PAK 18 MG/3 ML, is $30.6324 per ML — about 65% below VICTOZA 2-PAK 18 MG/3 ML PEN.
Who manufactures VICTOZA 2-PAK 18 MG/3 ML PEN?
VICTOZA 2-PAK 18 MG/3 ML PEN (NDC 00169406012) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Is VICTOZA 2-PAK 18 MG/3 ML PEN in shortage?
Yes — NDC 00169406012 is currently listed in FDA's drug shortage database (posted Jul 18, 2023). Reported reason: Delay in shipping of the drug.